Establishment of monitoring method for Ad-REIC-based therapeutic effects on cancer using the newly developed anti-REIC antibody that recognizes the cancer specific REIC conformation

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K18440
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Tumor diagnostics
• Research Institution: Okayama University
• Principal Investigator: Kinoshita Rie 岡山大学, 医歯薬学総合研究科, 助教 (40518297)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: REIC / 遺伝子治療 / がん

Outline of Final Research Achievements

Reduced expression in immortalized cells (REIC) is a tumor suppressor gene and has been studied as a promising therapeutic gene for cancer gene therapy. Intratumoral injection of adenovirus vector carrying the human REIC (Ad-REIC) elicits cancer cell-specific apoptosis and anti-cancer immune responses. In addition, Ad-REIC gene therapy resulted in complete response in the case of metastatic castration-resistant prostate cancer patient. We obtained various anti-REIC monoclonal antibodies and developed a sandwich ELISA method for measuring the REIC protein concentration in the human blood. Using this assay, we have successfully developed the method for monitoring cancer treatment with Ad-REIC.

Free Research Field

分子生物学